logo

TPST

Tempest Therapeutics·NASDAQ
--
--(--)
--
--(--)
2.80 / 10
Underperform

TPST's fundamentals receive a challenging rating of 2.8/10. Key concerns include a high PB-ROE value of 26.2260, negative Asset-MV (-0.5007) and Revenue-MV (-0.2574) differences, and a Net profit / Total profit ratio of 100%, suggesting limited earnings quality. Although Profit-MV is positive (0.4634), the overall factor profile points to sub-par fundamental strength and potential value traps.

Fundamental(2.8)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.26
Score1/3
Weight10.15%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.92%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.78%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight15.19%
1M Return7.79%
PB-ROE
Value26.23
Score1/3
Weight14.03%
1M Return7.02%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.78%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.30%
1M Return0.86%
Asset-MV
Value-0.50
Score2/3
Weight34.66%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight15.21%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.45%
1M Return-0.30%
Is TPST fundamentally strong?
  • TPST scores 2.80/10 on fundamentals and holds a Premium valuation at present. Backed by its -174.63% ROE, 0.00% net margin, -0.27 P/E ratio, 1.86 P/B ratio, and 51.11% earnings growth, these metrics solidify its Underperform investment rating.